Sareum Holdings and SRI International develop drug for inflammatory diseases

Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International.

Cancer drug discovery business Sareum Holdings has entered into a co-development agreement with research institute SRI International.

The two have joined forces to advance Sareum's Tyrosine Kinase 2 (TYK2) small molecule drug discovery programme for readiness in human clinical trials.

Research will focus on the development of small molecule the therapeutics targeting TYK2, one of the four janus kinase (JAK) family members implicated in a number of inflammatory diseases.

"The agreement with SRI gives us access to world-class autoimmune disease biology and drug development expertise," said Sareum's Chief Executive Officer Tim Mitchell.

"We are delighted to be working with SRI. As we have stated in the past, our intention has been to enter into agreements that help develop our research into commercially viable products in the most effective and efficient way."

SRI Biosciences' Center for Immunology and Infectious Diseases will co-lead discovery and development activities.

Annalisa D'Andrea, Senior Director of SRI's Center for Immunology and Infectious Diseases, added: "Because of TYK2's critical role in the signalling of inflammatory cytokines, there is strong scientific rationale for developing TYK2 inhibitors for the treatment of autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, sepsis, and Crohn's Disease."

Shares rose 7.32% to 1.10p at 08:19 Monday.

RD

Recommended

Three top-notch Asian stocks to buy
Share tips

Three top-notch Asian stocks to buy

Professional investors Adrian Lim and Pruksa Iamthongthong, managers of the Asia Dragon Trust, pick three of their favourite Asian stocks to buy now.
23 Sep 2022
Why you should short this satellite broadband company
Trading

Why you should short this satellite broadband company

With an ill-considered business plan, satellite broadband company AST SpaceMobile is doomed to failure, says Matthew Partridge. Here's how to short th…
23 Sep 2022
Share tips of the week – 23 September
Share tips

Share tips of the week – 23 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
23 Sep 2022
Momentum investing – and why price matters more than anything else
Investment strategy

Momentum investing – and why price matters more than anything else

The recent fashion for momentum investing, with investors piling into expensive growth stocks, is nothing new, says Merryn Somerset Webb. And the dang…
21 Sep 2022

Most Popular

Beating inflation takes more luck than skill – but are we about to get lucky?
Inflation

Beating inflation takes more luck than skill – but are we about to get lucky?

The US Federal Reserve managed to beat inflation in the 1980s. But much of that was down to pure luck. Thankfully, says Merryn Somerset Webb, the Bank…
26 Sep 2022
The pick of this year's best-performing investment trusts
Investment trusts

The pick of this year's best-performing investment trusts

Market conditions haven’t been easy, but these investment trusts have delivered strong growth, says David Stevenson.
23 Sep 2022
The hidden cost of employee share schemes
Investment strategy

The hidden cost of employee share schemes

Paying employees in shares comes at a cost to investors – but it isn’t always easy to see how much, says Stephen Clapham.
26 Sep 2022